Literature DB >> 2194349

A new perspective on canine keratoconjunctivitis sicca. Treatment with ophthalmic cyclosporine.

R L Kaswan1, M A Salisbury.   

Abstract

Keratoconjunctivitis sicca is the major cause of chronic or recurrent conjunctivitis in dogs. The diagnosis of KCS is often delayed or mistaken for allergic or bacterial conjunctivitis and inappropriate or insufficient treatment leads to progressive corneal scarring and blindness in many dogs. The cause of KCS in dogs has not been proven, but evidence supports an immune-mediated etiology for the majority of cases. In an attempt to specifically treat the cause of KCS, a new immunosuppressant drug, cyclosporine, has been used in a topical preparation. Treatment results using ophthalmic cyclosporine are dramatic compared with historical treatments. Resolution of corneal scarring and increased lacrimation are seen in most dogs. Investigations of the mechanism of action of ophthalmic cyclosporine suggest the efficacy may have been serendipitous. A local neuroendocrine effect of cyclosporine on the lacrimal gland may actually be responsible for the increased lacrimation. Early diagnosis of KCS and treatment with ophthalmic cyclosporine may avert a major cause of blindness in dogs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194349     DOI: 10.1016/s0195-5616(90)50052-2

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  16 in total

1.  Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model.

Authors:  Hiroshi Toshida; Doan H Nguyen; Roger W Beuerman; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-14       Impact factor: 4.799

2.  Comprehensive Clinical, Diagnostic, and Advanced Imaging Characterization of the Ocular Surface in Spontaneous Aqueous Deficient Dry Eye Disease in Dogs.

Authors:  Brian C Leonard; Kathleen A Stewart; Gillian C Shaw; Alyssa L Hoehn; Amelia A Stanley; Christopher J Murphy; Sara M Thomasy
Journal:  Cornea       Date:  2019-12       Impact factor: 2.651

3.  Diagnostic Ophthalmology.

Authors:  Marina L Leis; Lynne S Sandmeyer
Journal:  Can Vet J       Date:  2018-09       Impact factor: 1.008

4.  Allogeneic Mesenchymal Stem Cell Transplantation in Dogs With Keratoconjunctivitis Sicca.

Authors:  Maura K W Bittencourt; Michele A Barros; João Flávio P Martins; Jose Paulo C Vasconcellos; Bruna P Morais; Celine Pompeia; Matheus Domingues Bittencourt; Karine Dos Santos Evangelho; Irina Kerkis; Cristiane V Wenceslau
Journal:  Cell Med       Date:  2016-10-18

Review 5.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 6.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

7.  Identification of 9-O-acetyl-N-acetylneuraminic acid in normal canine pre-ocular tear film secreted mucins and its depletion in Keratoconjunctivitis sicca.

Authors:  A P Corfield; S R Donapaty; S D Carrington; S J Hicks; R Schauer; G Kohla
Journal:  Glycoconj J       Date:  2005-11       Impact factor: 3.009

8.  Impact of facial conformation on canine health: corneal ulceration.

Authors:  Rowena M A Packer; Anke Hendricks; Charlotte C Burn
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

9.  Effect of Withdrawing Chronic Topical Immune Modulating Treatment on Schirmer Tear Test Values in Dogs with Dry Eye Disease: Relevance to Dry Eye Studies.

Authors:  Shin Ae Park; Kathryn L Good; Sara M Thomasy; Philip H Kass; Christopher J Murphy
Journal:  J Ocul Pharmacol Ther       Date:  2021-07-07       Impact factor: 2.850

10.  Computed tomographic imaging characteristics of the normal canine lacrimal glands.

Authors:  Allison L Zwingenberger; Shin A Park; Christopher J Murphy
Journal:  BMC Vet Res       Date:  2014-05-22       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.